Philip Newsome

Philip Newsome

University of Birmingham

H-index: 74

Europe-United Kingdom

About Philip Newsome

Philip Newsome, With an exceptional h-index of 74 and a recent h-index of 54 (since 2020), a distinguished researcher at University of Birmingham, specializes in the field of liver, mesenchymal stromal cells, non-alcoholic fatty liver disease.

His recent articles reflect a diverse array of research interests and contributions to the field:

Glucagon-like peptide-1 receptor agonists in patients with cirrhosis-answering the unanswered questions?

Circulating myeloid populations have prognostic utility in alcohol-related liver disease

A Randomized Controlled Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

Reply: NAFLD–there ain’t no such thing as a free lunch

Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study

The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement

Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial

Philip Newsome Information

University

Position

___

Citations(all)

28885

Citations(since 2020)

22036

Cited By

12385

hIndex(all)

74

hIndex(since 2020)

54

i10Index(all)

165

i10Index(since 2020)

140

Email

University Profile Page

University of Birmingham

Google Scholar

View Google Scholar Profile

Philip Newsome Skills & Research Interests

liver

mesenchymal stromal cells

non-alcoholic fatty liver disease

Top articles of Philip Newsome

Title

Journal

Author(s)

Publication Date

Glucagon-like peptide-1 receptor agonists in patients with cirrhosis-answering the unanswered questions?

Clinical Gastroenterology and Hepatology: the Official Clinical Practice Journal of the American Gastroenterological Association

Sara Mahgoub

Philip N Newsome

2024/2/9

Circulating myeloid populations have prognostic utility in alcohol-related liver disease

Frontiers in immunology

Reenam Khan

Shees Salman

Laura Harford

Lozan Sheriff

Jon Hazeldine

...

2024/3/13

A Randomized Controlled Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis

New England Journal of Medicine

SA Harrison

P Bedossa

CD Guy

JM Schattenberg

R Loomba

...

2024

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis

New England Journal of Medicine

Stephen A Harrison

Pierre Bedossa

Cynthia D Guy

Jörn M Schattenberg

Rohit Loomba

...

2024/2/8

Reply: NAFLD–there ain’t no such thing as a free lunch

Hepatology

Jeffrey V Lazarus

Philip N Newsome

Mary E Rinella

2024/3/13

Translating the potential of the urine steroid metabolome to stage NAFLD (TrUSt-NAFLD): study protocol for a multicentre, prospective validation study

BMJ open

Hamish Miller

David Harman

Guruprasad Padur Aithal

Pinelopi Manousou

Jeremy F Cobbold

...

2024/1/1

The future of International Classification of Diseases coding in steatotic liver disease: An expert panel Delphi consensus statement

Hepatology communications

Hannes Hagström

Leon A Adams

Alina M Allen

Christopher D Byrne

Yoosoo Chang

...

2024/2/1

Vascular adhesion protein-1 blockade in primary sclerosing cholangitis: Open-label, multicenter, single-arm, phase II trial

Hepatology Communications

Gideon Hirschfield

Katie Arndtz

Amanda Kirkham

Yung-Yi Chen

Rich Fox

...

2024/1/23

The Impact of Stigma on Quality of Life and Liver Disease Burden Among Patients with Nonalcoholic Fatty Liver Disease

JHEP Reports

Zobair M Younossi

Saleh A AlQahtani

Jesús Funuyet-Salas

Manuel Romero-Gómez

Yusuf Yilmaz

...

2024/3/12

Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis

bioRxiv

Paul Horn

Jenny Norlin

Kasper Almholt

Birgitte M Viuff

Elisabeth D Galsgaard

...

2024

Reply:‘From NAFLD to MASLD: Promise and pitfalls of a new definition’

Hepatology

Mary E Rinella

Graciela E Castro Narro

Aleksander Krag

Norah Terrault

Philip N Newsome

2024/2/1

Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease

Journal of hepatology

Zobair M Younossi

Saleh A Alqahtani

Khalid Alswat

Yusuf Yilmaz

Caglayan Keklikkiran

...

2024/3/1

Paediatric steatotic liver disease has unique characteristics: A multisociety statement endorsing the new nomenclature

Journal of pediatric gastroenterology and nutrition

European Society for Pediatric Gastroenterology

Hepatology and Nutrition (ESPGHAN)

Ulrich Baumann

Bart GP Koot

Emer Fitzpatrick

...

2024/3/26

Implementation of a liver health check in people with type 2 diabetes

Kushala WM Abeysekera

Luca Valenti

Zobair Younossi

John F Dillon

Alina M Allen

...

2024/1/1

A global action agenda for turning the tide on fatty liver disease

Hepatology

Jeffrey V Lazarus

Henry E Mark

Alina M Allen

Juan Pablo Arab

Patrizia Carrieri

...

2024/2/1

Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study

Hepatology

Arvid Engström

Viktor Wintzell

Mads Melbye

Henrik Svanström

Björn Eliasson

...

2023/12/12

Vibration-controlled transient Elastography scores to predict liver-related events in Steatotic liver disease

JAMA

Huapeng Lin

Hye Won Lee

Terry Cheuk-Fung Yip

Emmanuel Tsochatzis

Salvatore Petta

...

2024/3/21

Reply: NAFLD, MAFLD, or MASLD? Cut the Gordian knot with “Ludwig disease”

Hepatology

Philip Newsome

Mary E Rinella

Jeffrey V Lazarus

Norah Terrault

2024/1/1

Transient Elastography Scores to Predict Liver-related Events in Steatotic Liver Disease: Agile scores in MASLD

JAMA-Journal of the American Medical Association

Philip Newsome

Sara Mahgoub

AGILE Team

2024/1/31

Investigation of jaundice

Sara Mahgoub

Reenam S Khan

Diarmaid D Houlihan

Philip N Newsome

2023/3/23

See List of Professors in Philip Newsome University(University of Birmingham)